TICKERNERD
Menu
XLOXLOHealthcare · Biotechnology

XLO Stock Forecast: Xilio Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$8.03
+3.35% on the day

The 2 Wall Street analysts covering Xilio Therapeutics, Inc. hold a median 12-month price target of $18 — +124.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$52.8M
Ticker Nerd rank
63/ 100
Median analyst target
$18
Analysts covering
2
Revenue$18.7M+131.2% y/y
Operating income−$3.5M
Net income−$6.4M
Free cash flow−$18.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.1%
1M
−11.3%
YTD
−10.4%
1Y
−28.7%
From 52W high
−32.5%
From 52W low
+12.5%
$7
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XLO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xilio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
63/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Growth
87
Size
80
Quality
79
Revisions
60
Momentum
49
Issuance
40
Accruals
20
Value
18

Volatility (97): The share price has been relatively steady.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XLO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XLO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26Oct 26XLOHigh $20Median $18Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $16Median $18High $20

The green dot is the last close — the median target sits +124.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Oct 2026Raymond JamesInitiatesOutperform$16
6 Aug 2025Leerink PartnersInitiatesOutperform$2.00
6 Aug 2025Leerink PartnersInitiatesOutperform—
8 Nov 2024Raymond JamesMaintainsOutperform—
30 May 2023Chardan CapitalReiteratesBuy—
11 May 2023Chardan CapitalReiteratesBuy—
27 Jan 2023Morgan StanleyMaintainsOverweight—
21 Dec 2022Chardan CapitalInitiatesBuy—
10 Nov 2022Raymond JamesMaintainsOutperform—
10 Aug 2022Morgan StanleyMaintainsOverweight—
10 Jan 2022HC Wainwright & Co.InitiatesBuy—
16 Nov 2021Cowen & Co.InitiatesOutperform—
16 Nov 2021Morgan StanleyInitiatesOverweight—
16 Nov 2021Raymond JamesInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XLO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XLO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Xilio Therapeutics, Inc. returned −28.7% against +12.4% for the S&P 500, dividends included.

XLO vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26XLOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XLO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Xilio Therapeutics, Inc. (XLO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 86% of US stocks

Price / sales
0.8×

Cheaper than 72% of US stocks

Price / book
0.7×

Cheaper than 78% of US stocks

EV / EBITDA
2.6×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
131.2%

Higher than 94% of US stocks

Earnings growth (YoY)
131.2%

Higher than 87% of US stocks

Gross margin
—
Operating margin
−18.7%

Higher than 22% of US stocks

Net margin
−34.1%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−55.0%

Higher than 20% of US stocks

Return on assets
−13.6%

Higher than 24% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xilio Therapeutics, Inc. (XLO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xilio Therapeutics, Inc. has a market value of $52.8M and an enterprise value of −$76.9M.

  • Revenue in the twelve months to 30 June 2026: $64.1M. The latest quarter grew 131.2% year on year.

  • Net income over the same four quarters: −$21.8M, a −34.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.64.

  • Free cash flow in the twelve months to 30 June 2026: −$61.3M.

  • Shares outstanding: 6.6M.

  • Trailing P/E: −1.9×; forward P/E: −13.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Xilio Therapeutics, Inc. employs 76 people — $843K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

XLO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XLOXilio Therapeutics, Inc.$52.8M63
HYFTMindWalk Holdings Corp.$52.8M50
HRTXHeron Therapeutics, Inc.$52.7M50
PLRXPliant Therapeutics, Inc.$53.2M73
INKTMiNK Therapeutics, Inc.$52.3M61
ONCYOncolytics Biotech, Inc.$54.2M35
ELOXEloxx Pharmaceuticals, Inc.$54.3M14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xilio Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XLO news & analysis

Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

GlobeNewsWire · 26 Oct 2026positive

Xilio Therapeutics announced that the first patient has been dosed in a Phase 1/2 clinical trial of XTX501 in patients with metastatic NSCLC. The company describes XTX501 as a novel PD-1/masked IL-2 bispecific with potential as a foundational backbone regimen for solid tumors.

Why it matters — The trial's first dose marks a clinical development milestone for XLO's XTX501 program.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Xilio Therapeutics announced inducement grants of non-qualified stock options under its 2022 Inducement Stock Incentive Plan, effective October 1, 2026, covering an aggregate of 100,895 shares for two new employees and 105,000 shares for newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D.

Why it matters — The grants signal the appointment and retention of new personnel, including a new Chief Medical Officer, indicating ongoing leadership and staffing developments at Xilio.

Xilio Therapeutics Appoints Yariv J. Houvras, M.D.

GlobeNewsWire · 28 Sept 2026positive

Xilio Therapeutics announced the appointment of Yariv J. Houvras, M.D., who brings over two decades of executive leadership in clinical development, translational medicine, and immuno-oncology across premier industry and academic research institutions.

Why it matters — A senior leader with deep expertise in clinical development and immuno-oncology joining the company could strengthen Xilio's leadership as it advances its pipeline.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Sept 2026neutral

Xilio Therapeutics announced that, effective September 1, 2026, it granted non-qualified stock options to purchase 19,865 shares of common stock to two new employees under its 2022 Inducement Stock Incentive Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The disclosure of new-employee inducement stock option grants gives XLO watchers insight into the company's equity compensation activity and recent hiring.

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

GlobeNewsWire · 12 Aug 2026positive

Xilio Therapeutics reported its second quarter 2026 financial results and provided pipeline and business updates. The company received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate, and is advancing IND-enabling studies for multi-specific masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND applications anticipated in the second half of 2027. The company said its cash runway into the first quarter of 2028 is expected to support key milestones across its pipeline.

Why it matters — The FDA clearance of the XTX501 IND and progress on its next-generation multi-specific masked immuno-oncology pipeline, supported by a cash runway into early 2028, signal XLO's continued advancement toward key clinical milestones.

FAQ

Frequently asked questions about XLO stock

What is the XLO stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Xilio Therapeutics, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XLO stock a buy right now?

Of the 2 analysts covering Xilio Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xilio Therapeutics, Inc. 63 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XLO?

As at 31 Oct 2026, Xilio Therapeutics, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will XLO stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +124.2% from the last close, and Ticker Nerd's factor model ranks Xilio Therapeutics, Inc. 63 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XLO stock forecast for 2030?

No analyst covering Xilio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $20 over the next 12 months.

How has XLO stock performed over the past year?

Xilio Therapeutics, Inc. returned -28.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xilio Therapeutics, Inc. do?

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer.

What is the latest news on XLO?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC". Xilio Therapeutics announced that the first patient has been dosed in a Phase 1/2 clinical trial of XTX501 in patients with metastatic NSCLC. The company describes XTX501 as a novel PD-1/masked IL-2 bispecific with potential as a foundational backbone regimen for solid tumors.

Company

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer. Its current portfolio centers on tumor-activated biologics designed to localize immune activity within the tumor microenvironment while aiming to reduce systemic side effects associated with broader immunotherapies. The company’s pipeline includes investigational checkpoint inhibitors, cytokines, and immune-cell engaging therapies, with programs spanning solid tumors and other cancer settings. Xilio Therapeutics also uses its proprietary platform to engineer tumor-selective molecules such as antibodies and cytokine-based candidates, which are intended to support more precise immune responses. Based in Waltham, Massachusetts, Xilio Therapeutics plays a role in advancing next-generation oncology treatments across the biotechnology and pharmaceutical markets.

CEO Dr. Rene Russo BCPS, Pharm.D. · 76 employees · United States · https://xiliotx.com